Blog

Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL – ALL Hub

Photo of Elias Jabbour from faculty.mdanderson.org

Jun 21, 2024, 09:47

Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL – ALL Hub

ALL Hub shared a post on X:

“CONGRESS | POSTER | EHA2024 | Elias Jabbour from MD Anderson Cancer Center reports follow-up for the phase III Golden Gate Study of blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with ND B-ALL. 13/14 (92.9%) patients had CR with blinatumomab and alternating LIC at the end of induction (~Week 14), 84.6% of these were MRD-negative. Acceptable safety profile.”

Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL - ALL Hub

Source: ALL Hub/X

ALL Hub blinatumomab cancer Congress EHA2024 Elias Jabbour Golden Gate Study induction LIC low-intensity chemotherapy MD Anderson Cancer Center MRD-negative older adults with ND B-ALL OncoDaily Oncology phase III poster safety profile

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage